Last updated: May 30, 2026
Dalfopristin and Quinupristin (Synercid) Clinical Trials Update, Market Analysis, and Exclusivity Outlook (2026)
Executive summary: Dalfopristin-quinupristin (fixed combination; brand Synercid) is a legacy, niche antibacterial regimen with limited, concentrated commercial pull driven by resistance trends and inpatient/specialty use constraints. The core clinical and regulatory base is mature, with no current broad late-stage development signal in major filings or trial registries at the level typically seen for active next-generation pipeline programs. Patent and exclusivity timing is fully out of the active launch era, shifting risk from primary exclusivity to formulation, method-of-use, and any product-specific manufacturing or regulatory exclusivity remnants, along with generic/authorized-indication entry dynamics.
What is dalfopristin; quinupristin and what is the current FDA status?
Direct answer: Dalfopristin (streptogramin B) plus quinupristin (streptogramin A) is an FDA-approved antibacterial combination marketed in the US under Synercid for infections due to susceptible Gram-positive organisms, including vancomycin-resistant Enterococcus faecium (VRE) in established prescribing contexts. The clinical value proposition has been strongest in settings where alternative agents are limited by resistance or toxicity profiles.
FDA approval scope and prescribing context
The FDA-approved combination is used for specified serious Gram-positive infections where susceptibility supports use. The regimen is administered IV. Clinical practice has remained niche because many Gram-positive infections can be treated with newer agents depending on susceptibility patterns, local antibiograms, and stewardship protocols.
Orange Book status: what to expect for legacy combinations
For older small-molecule combinations, Orange Book coverage typically breaks into:
- Active ingredient patents (often expired)
- Composition/formulation patents (often expired)
- Method-of-use patents (may persist longer, depending on prosecution history)
- Any FDA exclusivity (new chemical entity vs. not applicable for legacy molecules; pediatric exclusivity if ever triggered; depends on the original application timeline)
What patents protect dalfopristin; quinupristin and how strong is the estate?
Direct answer: Patent exclusivity is largely expired for the original dalfopristin and quinupristin combination era, so practical protection today usually comes from any remaining, narrower formulation or method-of-use claims that cover specific product parameters rather than foundational active-ingredient protection.
How to interpret “strength” for a legacy combination
For business decisions, estate strength for Synercid-style legacy antibacterials generally maps to:
- Remaining active patents in Orange Book (if any)
- Whether claims target manufacturing/process parameters that are hard to design around
- Whether any method-of-use claims are still enforceable and align with current labeling and real-world prescribing
Key estate categories that can still block entry
Even when broad composition protection is gone, blockages can remain via:
- Sterile IV formulation-specific patents
- Solubility/stability or combination preparation parameters
- Administration regimen details if claimed as method-of-use and matched to labeling
When does dalfopristin; quinupristin lose exclusivity?
Direct answer: Primary exclusivity tied to first marketing approval is largely exhausted for a legacy product like Synercid. Any remaining protection would typically be limited to later-issued, narrower patents and any non-expired exclusivity fragments tied to specific applications.
Exclusivity timeline mechanics
For a combination drug, exclusivity “loss” is not a single date unless a single blocking exclusivity period dominates. Instead, the practical “entry window” is the last-to-expire of:
- Last Orange Book-listed patent with a relevant claim
- Last non-expired exclusivity designation
- Litigation stays or settlements affecting FDA approval timing
Which clinical trials define efficacy for dalfopristin; quinupristin?
Direct answer: The combination’s efficacy is established by earlier randomized trials in serious Gram-positive infections where its streptogramin mechanism provided value, especially in VRE and difficult-to-treat scenarios. Late-stage pivotal data is historical, and the current development picture is more about competitive positioning than redefining core clinical endpoints.
Efficacy endpoints commonly used in the pivotal era
Typical trial constructs for serious Gram-positive infections include:
- Clinical cure at test-of-cure
- Microbiologic eradication or reduction
- Time to response
- Survival in severe infection subgroups (when included)
Safety profile drivers
Because the drug is IV and combination streptogramins can have characteristic adverse effects, tolerability and infusion-related considerations shape current use more than incremental mechanism advantages.
What is the latest clinical trials update for dalfopristin; quinupristin (2024-2026)?
Direct answer: No high-signal, broad late-stage development program is evident for dalfopristin-quinupristin in the way that would indicate imminent label expansion, line-of-therapy repositioning, or a new formulation seeking a new exclusivity anchor. The clinical footprint remains anchored in historical evidence and stewardship-led prescribing rather than active registrational trials.
What to look for in a “real” update
A meaningful 2024-2026 update would typically show up as:
- Phase 3 trials with registrational intent
- New combination regimens in Phase 2/3 with clear endpoints
- FDA supplemental labeling submissions tied to new trial results
- Manufacturing or formulation bridge studies aligned to a new NDA supplement
For this product class, absent that signal, the “update” is primarily market and policy driven, not R&D-driven.
How does dalfopristin; quinupristin compare with linezolid, daptomycin, and newer VRE options?
Direct answer: Competitive positioning depends on VRE susceptibility and toxicity/administration tradeoffs. Dalfopristin-quinupristin has historically been an option when resistant organisms limit choices, but modern stewardship often prioritizes agents with broader Gram-positive coverage and more convenient administration profiles.
Decision drivers in real-world use
- Susceptibility: VRE and specific resistance phenotypes
- IV logistics: infusion protocol complexity vs alternatives
- Adverse events: agent-specific tolerability
- Stewardship: local antibiogram and guideline alignment
What formulation patents protect dalfopristin; quinupristin and what do they cover?
Direct answer: The remaining formulation protection, if any, typically covers IV preparation attributes: stability, solubilization, compatibility, and storage. These are the patents most likely to matter for generic substitution because they can dictate technical feasibility and stability during compounding and infusion.
Where generic risk concentrates
For an IV antibiotic combination, generics face barriers in:
- Matching concentration and vehicle behavior
- Ensuring stability and shelf-life under label conditions
- Demonstrating bioequivalence where PK bridging is required for combination products
What generic entry risks exist for dalfopristin; quinupristin (ANDAs, 505(b)(2))?
Direct answer: Generic entry risk is usually moderated by economics and formulation complexity rather than broad active-ingredient patent cliffs. The main risk in practice is whether a sponsor can build an FDA-acceptable product (stability, compatibility, and regulatory pathway) at a scale that supports pricing.
How Paragraph IV would matter
If any Orange Book patents remain, an ANDA sponsor could file a Paragraph IV certification to challenge those patents, potentially triggering litigation and a potential 30-month stay depending on procedural posture. For legacy antibacterial combinations, the filing likelihood often tracks market size and whether patent cliffs are still near-term.
What patent litigation affects dalfopristin; quinupristin?
Direct answer: For a mature legacy product, litigation history tends to be historical and case-specific. The current relevance is whether any judgments or settlements define FDA approval timing for subsequent applicants.
Why litigation history matters for projection
In antibiotic generics, settlements can:
- Limit entry to specific launch dates
- Narrow claims to specific strengths/dosages
- Require exclusivity carve-outs for authorized generic launches
What is the competitive landscape for dalfopristin; quinupristin market share?
Direct answer: The market is specialized and tends to be driven by:
- VRE and other resistant Gram-positive infections
- Hospital formulary access and infectious disease stewardship policies
- Inventory management and IV antibiotic budgeting
Substitution patterns
Even when dalfopristin-quinupristin is active against the targeted organisms, it can be displaced by:
- Newer Gram-positive agents with more convenient regimens
- Institutional protocol changes after guideline updates
- Safety or cost comparisons at the hospital level
Market analysis: how much of the antibiotics market is dalfopristin; quinupristin exposed to?
Direct answer: Exposure is concentrated in the subset of hospitals that maintain access to a narrow VRE-focused IV option and in patient populations with susceptibility-driven need. The overall market opportunity is structurally limited by:
- Antibiotic stewardship restrictions
- Competition from modern Gram-positive antibiotics
- Narrow indication and susceptibility dependence
Where demand is most resilient
- Tertiary care centers with VRE caseloads
- ICUs and high-acuity inpatient wards with frequent resistant Gram-positive infections
- Settings with formulary flexibility for resistant organisms
Revenue projection for dalfopristin; quinupristin through 2028
Direct answer: A realistic base-case projection is low-to-modest net growth or steady demand with volatility by resistance epidemiology and hospital formulary decisions. The key ceiling is the narrowness of the indication and the willingness of stewardship committees to reserve alternative agents for broader use cases.
Projection model inputs that matter most
- Hospital VRE prevalence shifts (regional antibiograms)
- Inventory and purchasing behavior after stewardship policy changes
- Price erosion from any generic/authorized generic activity (if it occurs)
- Supply continuity and IV product availability
How does biosimilar risk apply to dalfopristin; quinupristin?
Direct answer: Biosimilar risk is not applicable because dalfopristin-quinupristin is a small-molecule antibiotic combination, not a biologic.
Key Takeaways
- Dalfopristin-quinupristin remains a legacy IV option with niche demand driven by resistant Gram-positive infection epidemiology.
- Clinical development is mature; the most meaningful “update” is market access and stewardship prescribing rather than active registrational trials.
- Exclusivity and patent blocking are likely largely exhausted for broad composition protections; any remaining protection is likely narrower (formulation/manufacturing/method-of-use), which matters for generic feasibility.
- Market projections should be treated as scenario-driven by VRE prevalence, guideline/stewardship alignment, and any future generic entry economics.
FAQs
- Is dalfopristin-quinupristin still used for VRE in 2026?
- What are the main safety and infusion-related considerations for Synercid?
- Does Synercid have active Orange Book patents today, and what claim types are they likely to cover?
- How would a generic dalfopristin-quinupristin entry affect pricing and hospital formulary behavior?
- What antibiotic stewardship criteria most influence when hospitals choose Synercid over alternatives?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-30).
- U.S. Food and Drug Administration. Synercid (dalfopristin/quinupristin) prescribing information. (Accessed 2026-05-30).
